Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis

Company Overview

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.63 million shs
• Average Volume: N/A
• Market Capitalization: $912.82 million
• P/E Ratio: N/A
• Dividend Yield: 2.96%
• Price Target: N/A
• Consensus Rating: N/A

BOT Stock Analysis - Frequently Asked Questions

How were Botanix Pharmaceuticals' earnings last quarter?

Botanix Pharmaceuticals Limited (ASX:BOT) issued its quarterly earnings results on Thursday, February, 28th. The company reported ($0.01) earnings per share for the quarter. Botanix Pharmaceuticals had a negative net margin of 670.20% and a negative trailing twelve-month return on equity of 18.00%.

What other stocks do shareholders of Botanix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Botanix Pharmaceuticals investors own include Alphabet (GOOG), Meta Platforms (META), Arafura Rare Earths (ARU), Canopy Growth (CGC), Manning & Napier (MN), (STB.TO) (STB) and (YCB) (YCB).

Company Calendar

• Last Earnings: 2/28/2019
• Today: 2/23/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:BOT
• CUSIP: N/A
• CIK: N/A
• Web: www.botanixpharma.com
• Phone: +61-8-94820580
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,870,000.00
• Net Margins: -670.20%
• Pretax Margin: N/A
• Return on Equity: -18.00%
• Return on Assets: -12.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.21
• Quick Ratio: 1.26

Sales & Book Value

• Annual Sales: $2.07 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 1.50
• Book Value: A$0.07 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,810,000,000
• Free Float: N/A
• Market Cap: $912.82 million
• Optionable: Not Optionable
• Beta: 1.71